Patients with AIHA due to IgG often present with symptoms related to anemia and the destruction of red blood cells. Common symptoms include:

• Fatigue and weakness
• Shortness of breath
• Pale or yellowish skin (jaundice)
• Dark-colored urine
• Rapid heartbeat
• Dizziness or lightheadedness

These symptoms can vary in severity and may develop gradually or suddenly.

Diagnosing AIHA involves several steps:

1. Medical History and Physical Examination: A thorough history and examination can reveal signs of anemia and jaundice.

2. Blood Tests:

   • Complete Blood Count (CBC): To check for anemia.
   • Reticulocyte Count: To assess bone marrow response.
   • Bilirubin Levels: Elevated levels indicate increased red blood cell destruction.
   • Lactate Dehydrogenase (LDH): Often elevated in hemolysis.
   • Haptoglobin: Typically low in hemolysis.

3. Direct Antiglobulin Test (DAT or Coombs Test): This test detects antibodies attached to red blood cells, confirming AIHA.

4. Additional Tests: Depending on the suspected underlying cause, further tests may be needed to rule out other conditions.

Treatment for AIHA due to IgG focuses on reducing the immune system's attack on red blood cells and managing symptoms:

• Corticosteroids: Often the first line of treatment to suppress the immune response.
• Immunosuppressive Drugs: Used if steroids are ineffective or cause significant side effects.
• Blood Transfusions: May be necessary in severe cases to quickly increase red blood cell count.
• Splenectomy: Surgical removal of the spleen may be considered if other treatments fail, as the spleen is involved in destroying antibody-coated red blood cells.

The prognosis for AIHA varies. Some patients respond well to treatment and experience long periods of remission, while others may have chronic or recurrent episodes. Early diagnosis and appropriate management are crucial for improving outcomes.

The exact cause of AIHA is often unknown, but it can be associated with:

• Autoimmune disorders (e.g., lupus)
• Infections
• Certain medications
• Lymphoproliferative disorders (e.g., lymphoma)

In some cases, no underlying cause is identified, and the condition is termed "idiopathic."

AIHA is a rare condition, with an estimated incidence of 1-3 cases per 100,000 people per year. It can occur at any age but is more common in adults. Women are slightly more affected than men.

In AIHA due to IgG, the immune system produces IgG antibodies that mistakenly target red blood cells. These antibodies bind to the red blood cells, marking them for destruction by the spleen and other parts of the immune system. This leads to hemolysis (destruction of red blood cells) and anemia.

There is no specific way to prevent AIHA due to IgG, as the exact cause is often unknown. However, managing underlying conditions and avoiding known triggers (such as certain medications) may help reduce the risk.

Autoimmune Hemolytic Anemia due to IgG is a rare condition where the immune system attacks red blood cells, leading to anemia. It presents with symptoms like fatigue and jaundice and is diagnosed through blood tests and the Coombs test. Treatment involves immunosuppressive therapies and, in some cases, blood transfusions or splenectomy. The prognosis varies, and while the exact cause is often unknown, it can be associated with other medical conditions.

If you have been diagnosed with Autoimmune Hemolytic Anemia due to IgG, it's important to understand that this condition involves your immune system attacking your red blood cells. This can make you feel tired and weak, and you might notice your skin looking pale or yellow. Treatment usually involves medications to calm your immune system and, sometimes, blood transfusions. Your doctor will work with you to find the best treatment plan. Regular follow-ups and monitoring are essential to manage this condition effectively.